ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Rating of “Buy” by Analysts

Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) have received an average recommendation of “Buy” from the ten analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have covered the stock in the last year is $84.75.

Several brokerages have commented on ANIP. Piper Sandler reissued an “overweight” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. HC Wainwright reissued a “buy” rating and set a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research report on Friday, August 8th. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 21st. Guggenheim restated a “buy” rating and issued a $86.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, May 12th. Finally, Truist Financial raised their target price on shares of ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a “hold” rating in a research note on Monday, August 11th.

Insider Transactions at ANI Pharmaceuticals

In related news, CFO Stephen P. Carey sold 50,000 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $86.07, for a total value of $4,303,500.00. Following the transaction, the chief financial officer owned 180,863 shares in the company, valued at $15,566,878.41. The trade was a 21.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Chad Gassert sold 20,000 shares of the stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $86.97, for a total transaction of $1,739,400.00. Following the sale, the senior vice president owned 173,226 shares in the company, valued at approximately $15,065,465.22. The trade was a 10.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 405,538 shares of company stock worth $35,690,131 over the last quarter. Corporate insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

Several large investors have recently modified their holdings of ANIP. Millennium Management LLC increased its holdings in ANI Pharmaceuticals by 89.3% during the fourth quarter. Millennium Management LLC now owns 1,002,849 shares of the specialty pharmaceutical company’s stock valued at $55,437,000 after buying an additional 473,097 shares during the last quarter. Rubric Capital Management LP raised its holdings in ANI Pharmaceuticals by 354.7% in the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company’s stock worth $16,813,000 after purchasing an additional 200,998 shares during the period. Aberdeen Group plc raised its holdings in ANI Pharmaceuticals by 76.1% in the 1st quarter. Aberdeen Group plc now owns 419,099 shares of the specialty pharmaceutical company’s stock worth $28,059,000 after purchasing an additional 181,134 shares during the period. Woodline Partners LP purchased a new position in ANI Pharmaceuticals during the first quarter valued at $11,144,000. Finally, Deep Track Capital LP grew its holdings in ANI Pharmaceuticals by 28.6% during the fourth quarter. Deep Track Capital LP now owns 649,042 shares of the specialty pharmaceutical company’s stock valued at $35,879,000 after purchasing an additional 144,214 shares during the period. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ ANIP opened at $94.10 on Wednesday. The firm has a fifty day simple moving average of $74.48 and a two-hundred day simple moving average of $67.55. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $95.60. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $2.04 billion, a PE ratio of -122.21 and a beta of 0.63.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business had revenue of $211.37 million during the quarter, compared to analyst estimates of $187.18 million. During the same period last year, the business posted $1.02 earnings per share. ANI Pharmaceuticals’s quarterly revenue was up 53.2% compared to the same quarter last year. Equities analysts expect that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.